Clonal hematopoiesis in long-term survivors after allogeneic hematopoietic cell transplantation: associations with active chronic graft-versus-host disease, donor age, and transplantation for chronic myeloid leukemia

Clonal hematopoiesis (CH) in long-term survivors of allogeneic hematopoietic cell transplant (HCT) remains largely understudied. Using targeted sequencing, we analyzed peripheral blood samples from 101 patients who survived without relapse for more than 10 years after HCT. The median interval from HCT to sample collection was 13.8 years (range, 10.0-29.8 years). Thirty-six CHs with ≥2% variant allele frequency were detected in 29 patients (28.7%). Complete blood count did not differ according to CH status. Multivariable analysis showed donor age at sampling (odds ratio [OR] 1.06, 95% confidence interval [CI] 1.00-1.12), patients who underwent HCT for chronic myeloid leukemia (CML; OR 7.13, 95% CI 1.38-36.8), and moderate/severe chronic graft-versushost disease at sampling (OR 5.49, 95% CI 1.05-28.7) were significantly associated with CH. Donor age at sampling was significantly higher in patients with pathogenic CH than in those with variants of unknown significance or those without CH (median 56.5 vs 48.0 vs 47.0 years old, p=0.0077). After a median follow-up of 60.0 months after sampling, one patient with CML experienced relapse. Three-year Overall survival (94.2% vs. 92.9%, p=0.800) and cumulative incidence of second cancer (18.0% vs. 14.9%, p=0.410) after CH sampling were not associated with CH status. In conclusion, CH in HCT survivors is common and associated with donor age, transplantation for CML, and chronic graftversus-host disease.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-11-12
DOI
https://doi.org/10.3324/haematol.2026.301340
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clonal hematopoiesis in long-term survivors after allogeneic hematopoietic cell transplantation: associations with active chronic graft-versus-host disease, donor age, and transplantation for chronic myeloid leukemia

Takashi Toya, Yuka Harada, Kaoru Morita, Daichi Sadato et al.
Haematologica
Hematopoietic Stem Cell Transplantation
article

Clonal hematopoiesis in long-term survivors after allogeneic hematopoietic cell transplantation: associations with active chronic graft-versus-host disease, donor age, and transplantation for chronic myeloid leukemia

Takashi Toya, Yuka Harada, Kaoru Morita, Daichi Sadato, Noriko Doki, Hironori Harada, Hiroaki Shimizu, Chizuko Hirama, Tomomi Toubai, Atsushi Jinguji, Yuho Najima, Yasutaka Sadaga, Kaori Kondo, Kana Kato, Kyoko Haraguchi
article en

Abstract

Clonal hematopoiesis (CH) in long-term survivors of allogeneic hematopoietic cell transplant (HCT) remains largely understudied. Using targeted sequencing, we analyzed peripheral blood samples from 101 patients who survived without relapse for more than 10 years after HCT. The median interval from HCT to sample collection was 13.8 years (range, 10.0-29.8 years). Thirty-six CHs with ≥2% variant allele frequency were detected in 29 patients (28.7%). Complete blood count did not differ according to CH status. Multivariable analysis showed donor age at sampling (odds ratio [OR] 1.06, 95% confidence interval [CI] 1.00-1.12), patients who underwent HCT for chronic myeloid leukemia (CML; OR 7.13, 95% CI 1.38-36.8), and moderate/severe chronic graft-versushost disease at sampling (OR 5.49, 95% CI 1.05-28.7) were significantly associated with CH. Donor age at sampling was significantly higher in patients with pathogenic CH than in those with variants of unknown significance or those without CH (median 56.5 vs 48.0 vs 47.0 years old, p=0.0077). After a median follow-up of 60.0 months after sampling, one patient with CML experienced relapse. Three-year Overall survival (94.2% vs. 92.9%, p=0.800) and cumulative incidence of second cancer (18.0% vs. 14.9%, p=0.410) after CH sampling were not associated with CH status. In conclusion, CH in HCT survivors is common and associated with donor age, transplantation for CML, and chronic graftversus-host disease.

Haematologica
Tokyo University of Pharmacy and Life Sciences (JP), Tokyo Metropolitan Komagome Hospital (JP), Dokkyo Medical University (JP)
Tokyo Metropolitan Government, Japan Society for the Promotion of Science
Good health and well-being
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon